Clinical trial · Observational
Tumor Budding in Patients With Colorectal Cancer Under Different MMR Status
Prognostic Impact of Tumor Budding and Tumor-infiltrating Lymphocytes in Patients With Colorectal Cancer Under Different MMR Status: A Single-Center, Open-Label, Retrospective, Observational Cohort Study
NCT05610592CI-TRIAL-00062082completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the ability of tumor budding to identify prognosis in different MMR states and different levels of tumor lymphocyte infiltration. Tumor budding is usually defined as an isolated single cancer cell or a cluster of up to four cancer cells located at the front of an infiltrating tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
| Tumor Budding | Rectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| total mesorectal exicision | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Rectal cancer
- description
- patients underwent curative surgery
- interventionNames
- Procedure: total mesorectal exicision
Primary outcomes (1)
- measure
- 5-year event-free survival rate
- timeFrame
- 5 years after the surgery
Secondary outcomes (2)
- measure
- 5-year overall survival rate
- timeFrame
- 5 years after the surgery
- measure
- Local recurrence
- timeFrame
- 5 years after the surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed colorectal adenocarcinoma cancer pathologically 2. Underwent primary surgery 3. With records for tumor budding staining 4. Willing and able to provide written informed consent for participation in this study 5. Non-complicated primary tumor (complete obstruction, perforation, bleeding) Exclusion Criteria: 1. With distant metastases at the time of initial diagnosis 2. Without a complete pathological date 3. Hereditary colorectal cancer 4. Subjects with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer
References
Publications (1)
- DERIVEDXie H, Zeng Z, Hou Y, Ye F, Cai T, Cai Y, Xiong L, Li W, Liu Z, Liang Z, Luo S, Zheng X, Huang L, Liu H, Kang L. Effects of tumour budding on adjuvant chemotherapy in colorectal cancer. BJS Open. 2024 Jan 3;8(1):zrad115. doi: 10.1093/bjsopen/zrad115. PMID 38190579